LADR Platform

Smart Drug Development Technology

The Future of Drug Development

LADR combines proven scientific principles with a focused development strategy to accelerate improved therapies from known drug starting points.

Smarter Chemistry. Faster Approvals. Lower Risk.*

LADR — Ligand-Assisted Drug Remodeling Creates Upgraded Versions of Many Proven and Approved Medicines.

LADR is a covalent prodrug remodeling approach designed to improve PK, tolerability, solubility, and IP position across multiple scaffold classes.

*Relative to de novo development.

LADR covalent remodeling visual showing an approved molecule transformed into a remodeled new chemical entity through ligand-assisted chemistry

The Four Pillars

A comprehensive approach to improving drug products with maximum flexibility.

Repurpose

Use an existing drug for a new indication.

Reprofile

Create better dosing or pediatric formulations to improve tolerance and efficacy.

Reposition

Modify a drug to overcome barriers such as solubility so it works better, including changing route of dosing.

Rescue

Revive assets that were failing due to absorption or tolerability limitations through chemical modification.

How LADR Works

Starting with drug substances already approved for human use, LADR applies a modifying agent from a curated library to create an improved, patentable drug. LADR is a chemical modification approach, not a formulation, and does not trigger a 505(b)(1) path.

Chemical Modification

Not a formulation change, but chemical modification designed to create improved molecular entities.

Patent Protection

Creates new, patentable New Chemical Entities with a differentiated development path.

Key Advantages

The platform is designed for speed, cost discipline, and risk reduction.

Develop approximately 4x faster as compared to de novo drug development.

~5% of cost as compared to de novo drug development.

Higher probability of success as compared to de novo drug development.

Chemical modification creates patentable New Chemical Entities while avoiding the 10-12 year, $1-3B 505(b)(1) path.

Ready to Transform Drug Development?

Join Ladrion Therapeutics in advancing affordable therapies through smarter drug development.